Research programme : anti-fibrotic therapeutics - ProMetic Life Sciences

Drug Profile

Research programme : anti-fibrotic therapeutics - ProMetic Life Sciences

Alternative Names: PBI-4425; PBI-4547

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ProMetic Life Sciences
  • Class Small molecules
  • Mechanism of Action Cell differentiation modulators; Collagen inhibitors; Colony stimulating factor stimulants; Cytokine modulators; Erythropoiesis stimulants; Extracellular matrix protein inhibitors; Immunomodulators; Inflammation mediator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic nephropathies; Hepatic fibrosis; Idiopathic pulmonary fibrosis; Scleroderma

Most Recent Events

  • 14 Aug 2017 PBI 4547, PBI 4425 licensed to Prometic ChinaCo for development in China
  • 23 May 2017 Preclinical trials in Scleroderma in Canada (PO)
  • 23 May 2017 Pharmacodynamics data from a preclinical trial in Scleroderma released by ProMetic Lifesciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top